Islam M, Barshetty M, Srinivasan S, Dudekula D, Rallabandi V, Mohammed S
Biomolecules. 2022; 12(9).
PMID: 36139117
PMC: 9496582.
DOI: 10.3390/biom12091279.
Lee Y, Oh S, Kim K, Go S, Kim J, Huh S
Cancers (Basel). 2022; 14(8).
PMID: 35454857
PMC: 9029419.
DOI: 10.3390/cancers14081950.
Abdel-Rahman O, Elsayed Z, Elhalawani H
Cochrane Database Syst Rev. 2018; 4:CD011746.
PMID: 29624208
PMC: 6494548.
DOI: 10.1002/14651858.CD011746.pub2.
Guest R, Boulter L, Dwyer B, Forbes S
NPJ Regen Med. 2018; 2:13.
PMID: 29302349
PMC: 5677951.
DOI: 10.1038/s41536-017-0018-z.
Gabriel E, Gandhi S, Attwood K, Kuvshinoff B, Hochwald S, Iyer R
J Gastrointest Oncol. 2017; 8(4):728-736.
PMID: 28890824
PMC: 5582046.
DOI: 10.21037/jgo.2017.01.24.
Targeted therapy in biliary tract cancers-current limitations and potentials in the future.
Sahu S, Sun W
J Gastrointest Oncol. 2017; 8(2):324-336.
PMID: 28480071
PMC: 5401865.
DOI: 10.21037/jgo.2016.09.16.
Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function.
Gong J, Cho M, Fakih M
J Gastrointest Oncol. 2017; 8(2):314-323.
PMID: 28480070
PMC: 5401853.
DOI: 10.21037/jgo.2016.09.17.
Signaling pathways as therapeutic targets in biliary tract cancer.
Yang J, Farren M, Ahn D, Bekaii-Saab T, Lesinski G
Expert Opin Ther Targets. 2017; 21(5):485-498.
PMID: 28282502
PMC: 6751570.
DOI: 10.1080/14728222.2017.1306055.
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff L, Cardin D, Whisenant J, Du L, Koyama T, Dahlman K
Invest New Drugs. 2016; 35(1):95-104.
PMID: 27853997
PMC: 5306261.
DOI: 10.1007/s10637-016-0406-z.
Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients.
Mao Z, Guo X, Su D, Wang L, Zhang T, Bai L
Med Sci Monit. 2015; 21:2375-81.
PMID: 26269932
PMC: 4540057.
DOI: 10.12659/MSM.893586.
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.
Sio T, Martenson Jr J, Haddock M, Novotny P, Gores G, Alberts S
Am J Clin Oncol. 2014; 39(3):271-5.
PMID: 24921218
PMC: 4309741.
DOI: 10.1097/COC.0000000000000056.
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
Denlinger C, Meropol N, Li T, Lewis N, Engstrom P, Weiner L
Clin Colorectal Cancer. 2014; 13(2):81-6.
PMID: 24512954
PMC: 4189831.
DOI: 10.1016/j.clcc.2013.12.005.
Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.
Nagai H, Kitano T, Nishimura T, Yasuda H, Nakata K, Takashima S
Support Care Cancer. 2013; 21(12):3271-8.
PMID: 23877927
DOI: 10.1007/s00520-013-1901-9.
A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1.
Lim J, Ryu J, Choi Y, Kwon J, Kim J, Lee Y
Gut Liver. 2013; 7(3):371-6.
PMID: 23710321
PMC: 3661972.
DOI: 10.5009/gnl.2013.7.3.371.
Advances in the management of biliary tract cancers.
Ciombor K, Goff L
Clin Adv Hematol Oncol. 2013; 11(1):28-34.
PMID: 23416860
PMC: 3713630.
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.
Hayashi T, Ishiwatari H, Yoshida M, Sato T, Miyanishi K, Sato Y
Int J Clin Oncol. 2011; 17(5):491-7.
PMID: 21932164
DOI: 10.1007/s10147-011-0320-5.
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
Williams K, Picus J, Trinkhaus K, Fournier C, Suresh R, James J
HPB (Oxford). 2010; 12(6):418-26.
PMID: 20662793
PMC: 3028583.
DOI: 10.1111/j.1477-2574.2010.00197.x.
Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.
Kohya N, Kitahara K, Miyazaki K
World J Gastroenterol. 2010; 16(28):3567-72.
PMID: 20653066
PMC: 2909557.
DOI: 10.3748/wjg.v16.i28.3567.
Current management of gallbladder carcinoma.
Zhu A, Hong T, Hezel A, Kooby D
Oncologist. 2010; 15(2):168-81.
PMID: 20147507
PMC: 3227945.
DOI: 10.1634/theoncologist.2009-0302.
EGFR expression in gallbladder carcinoma in North America.
Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y
Int J Med Sci. 2008; 5(5):285-91.
PMID: 18825277
PMC: 2556051.
DOI: 10.7150/ijms.5.285.
